Q2 2026 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Glenmark Pharmaceuticals Ltd (BOM:532296) reported a significant year-over-year revenue growth of 76% for Q2 FY26, with consolidated revenue from operations reaching INR60,469 million.
- The company has successfully launched several new products in India, including TEVIMBRA and BRUKINSA, which have shown strong market uptake.
- Glenmark's North America business recorded a substantial increase in sales, driven by new product launches and a strong institutional business franchise.
- The European operations returned to growth with an 8.5% increase in sales, supported by robust uptake of new product launches and a strong branded respiratory portfolio.
- Glenmark has entered a new phase called Glenmark 3.0, focusing on becoming a branded-led company globally, with expectations of strong revenue growth and improved operating margins.
- The India formulation business experienced a significant decline in sales by 87% due to the GST regime change, leading to reduced distributor inventory levels and postponed orders.
- Emerging markets revenues declined by 6.5% due to geopolitical uncertainties affecting sales in Latin America and the Middle East, Africa.
- The company faced challenges with its legacy 3-tier distribution system in India, which was impacted by the GST regime change, causing disruptions in primary sales.
- Glenmark had to make onetime provisions and charges related to debtors and inventory, impacting financial metrics.
- The company incurred significant onetime expenses, including bonuses and deal execution costs, following the ISB 2001 deal, which affected cash flow.
Good morning, ladies and gentlemen. Welcome to the Q2 FY26 earnings conference call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Utkarsh Gandhi, Senior General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Thank you, Lizan. Good morning, everyone, and welcome to the Q2 FY26 Earnings Conference Call of Glenmark Pharmaceuticals Limited.
Before we start the call, a quick reminder to everyone that the information, statements and analysis discussed during this call describing the company's or affiliates, objectives, projections and estimates are forward-looking statements based on current expectations, forecasts and assumptions, which are subject to system uncertainties, which could cause the actual outcomes to differ materially, and more representation of warranty either expressed or implied is provided in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
